4.7 Article

Probing the Plasticity in the Active Site of Protein N-terminal Methyltransferase 1 Using Bisubstrate Analogues

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 63, Issue 15, Pages 8419-8431

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.0c00770

Keywords

-

Funding

  1. NIH [R01GM117275, 1R01GM127896, 1R01AI127793, P30 CA023168]
  2. AbbVie
  3. Bayer Pharma AG
  4. Canada Foundation for Innovation
  5. Genome Canada through Ontario Genomics Institute [OGI-055]
  6. Innovative Medicines Initiative (EU/EFPIA) [115766]
  7. Janssen
  8. Merck KGaA, Darmstadt, Germany
  9. Boehringer Ingelheim
  10. Eshelman Institute for Innovation
  11. MSD
  12. Novartis Pharma AG
  13. Ontario Ministry of Research, Innovation and Science (MRIS)
  14. Pfizer
  15. Sao Paulo Research Foundation-FAPESP
  16. Takeda
  17. Wellcome
  18. Department of Medicinal Chemistry and Molecular Pharmacology
  19. Department of Biological Sciences at Purdue University
  20. Natural Sciences and Engineering Research Council [RGPIN-2016-06300]

Ask authors/readers for more resources

The bisubstrate analogue strategy is a promising approach to develop potent and selective inhibitors for protein methyltransferases. Herein, the interactions of a series of bisubstrate analogues with protein N-terminal methyltransferase 1 (NTMT1) were examined to probe the molecular properties of the active site of NTMT1. Our results indicate that a 2-C to 4-C atom linker enables its respective bisubstrate analogue to occupy both substrate- and cofactor-binding sites of NTMT1, but the bisubstrate analogue with a 5-C atom linker only interacts with the substrate-binding site and functions as a substrate. Furthermore, the 4-C atom linker is the optimal and produces the most potent inhibitor (K-i,K-app = 130 +/- 40 pM) for NTMT1 to date, displaying more than 3000-fold selectivity for other methyltransferases and even for its homologue NTMT2. This study reveals the molecular basis for the plasticity of the active site of NTMT1. Additionally, our study outlines general guidance on the development of bisubstrate inhibitors for any methyltransferases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available